Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Unum Therapeutics initiates phase I trial of antibody-coupled T-cell receptor therapy

Dec. 3, 2014

GlaxoSmithKline presents preclinical data for the anti-HER3 antibody GSK-2849330

Dec. 2, 2014

Promising phase IIb results presented from the TIME trial evaluating TG-4010 in NSCLC

Dec. 2, 2014

First-in-human study of OBT-357 begins in acute myeloid leukemia

Nov. 26, 2014

Primary endpoint met in phase II study of TriMix-DC-MEL melanoma vaccine

Nov. 25, 2014

Amgen terminates all Amgen-sponsored studies of rilotumumab in advanced gastric cancer

Nov. 25, 2014

First clinical data showed that KTN-3379 is well tolerated in advanced solid tumors

Nov. 25, 2014

Novogen identifies lead ATM drug candidate

Nov. 25, 2014

AstraZeneca Canada confirms global lung cancer study of MED-14736

Nov. 21, 2014

New financings support Northwest Biotherapeutics' development of DCVax-L and DCVax-Direct

Nov. 21, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...